News
13 May 2022
Investigating the Impact of COVID-19 on Cognition
Children of the 90s collaborates with researchers at Cambridge Cognition to investigate the cognitive impacts of COVID-19.
Read on
16 December 2021
Electronic Clinical Outcomes Assessment contract win worth over £500,000
Cambridge Cognition is pleased to announce that it has won a contract worth over £500,000 to provide electronic clinical outcome assessments ("eCOA").
Read on
9 December 2021
Cambridge Cognition wins £1.0m schizophrenia clinical trial contract
Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for an additional schizophrenia clinical trial worth £1.0m.
Read on
26 October 2021
Cambridge Cognition wins contract for a pivotal schizophrenia trial
Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for a further sizeable schizophrenia trial with an existing customer.
Read on
6 August 2021
Cambridge Cognition: COVID-19 Update
We would like to update you on the steps Cambridge Cognition is taking to ensure business continuity for all our customers as the widespread impact of COVID-19 (coronavirus) continues to affect so many globally.
Read on
1 July 2021
Spin-out of Monument Therapeutics
Cambridge Cognition is pleased to announce the completion of the spin-out of Monument Therapeutics, a drug development company applying digital phenotyping to central nervous system ("CNS") disorders.
Read on
28 June 2021
New £2.2 million contract for at-home cognitive testing in a virtual clinical trial
Cambridge Cognition has been selected as the cognitive assessment partner for a large at-home study. The contract is valued at £2.2 million with revenue expected to be recognised by the Company over three years beginning in H2 2021.
